Car t-cell therapy for solid tumors that have a cd276 marker
Part of Cancer clinical trials.
This trial tests a special type of cell therapy called CAR T cells. The cells are changed in the lab to find and attack a protein called CD276 on the surface of solid tumors. If the treatment works, your own immune cells could shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be positive for a marker called CD276 (B7-H3). This is found by a biopsy test.
- You have already tried at least one standard treatment, but the cancer is still growing, has spread, or cannot be removed with surgery.
- You must be between 1 and 75 years old and weigh at least 10 kilograms (22 pounds).
- Your overall health should be fairly good (performance status of 60% or more). This means you can care for yourself and are out of bed most of the day.
- Your heart, lungs, liver, kidneys, and blood counts need to be within certain limits, and you must have enough oxygen in your blood without extra oxygen.
- You cannot have an untreated brain tumor, certain active infections (HIV, hepatitis B or C), or be on strong immune-suppressing medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This study tests a special immune cell treatment (CAR T cells) that targets a marker called GD2 on solid tumor cells. It is for people whose cancer has not responded to standard treatments or has come back.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This trial tests a personalized cell therapy where your own immune cells are collected, modified to better attack cancer, and then returned to you. It is for people with various solid tumors and lymphomas whose cancer cells have specific markers.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack tumors with specific markers (GD2 or CD70). It may be an option for patients whose cancer has not responded to standard treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.